Max Bricchi has over twenty-five years of experience and leadership across Regional and Global Strategy, Marketing, Commercial, and end-to-end Portfolio Management. Max brings a broad background in the pharmaceutical industry from several roles, having a strong track record in pre-launch and launch of products across several therapeutical areas, including neurology, rheumatology, gastroenterology, dermatology, and rare diseases.

Max Bricchi joined BIAL on 1 March 2023 as Chief Commercial Officer (CCO) and Executive Board Member, coming from Novartis (HQ, Basel, Switzerland) where, since 2020, he served as the Global Head Neuroscience Franchise. For 15 years, from 2005 to 2020, Max Bricchi served at UCB, where he undertook different positions in various locations of the company: Global Head Epilepsy Franchise, Japan, China, and International Markets Head Neurology - both positions based in Belgium -, Latin America Region Managing Director based in Mexico, US Group Director Immunology and Global and US Brand Director Biologics based in the United States.

Max´s professional career in the pharmaceutical industry started in 2002 at Schering-Plough Corporation as Global Product Manager of Immunology, in the US, and then in Germany as Immunology Division Manager.

Max Bricchi holds an MBA from IMD Lausanne, a Master’s in Quality Management from Buenos Aires Technologic Institute, and a degree as an Industrial Engineer from the University of Buenos Aires, Argentina.